EPCT.PK

EpiCept Corporation

Justin M. Hall
(EPCT.PK) Nearing oversold levels. Best entry at or near 50-day, $0.66. Rx Investors.com

Justin M. Hall
(EPCT.PK) Ceplene for A-M-L just approved in Israel. Shares likely to continue climbing higher. => Rx Investors.com

Justin M. Hall
(EPCT.PK) Shares have climbed +42% (60 days) from my previous coverage of Co here at SA back on 10/15/10 => Rx Investors.com

Justin M. Hall
(EPCT.PK) NCI initiated P2 trial with crolibulin in pts w/ Anaplastic Thyroid Cancer => Rx Investors.com

Justin M. Hall
PLAY DEFENSE: (ANIK), (EPCT.PK), (GHDX), (OXGN), (VNDA) all performing well today => Rx Investors.com

Justin M. Hall
Rx Investors.com: Orphan Drug & Fast Track Index > SPPI, EPCT.PK, VNDA, CYTK, CLDX, ZIOP, IMGN, KERX, BVTI.PK, AEZS > http://seekingalpha.com/p/2cge

Justin M. Hall
(EPCT.PK) EpiCept Agrees to FDA's Plan for Ceplene + My Thoughts on Meda AB and GSK => Rx Investors.com => http://seekingalpha.com/p/29kf

Justin M. Hall
Pre-Market Pops (EPCT.PK) +16.91%; MEDQ.PK-RETIRED, SVNT, SWC are all up respectfully. => Regarding EPCT: http://bit.ly/98wSlw => Rx Investors.com =>

Justin M. Hall
(EPCT.PK) EpiCept Agrees to FDA's Plan for Ceplene => Rx Investors.com => http://bit.ly/98wSlw

Justin M. Hall
(EPCT.PK) Partner for cancer pain drug NP-1 may be found; expecting announcement year-end 2010. => Rx Investors.com => http://bit.ly/cRBMV1